IRB FEE SCHEDULE

	Initial Full Board Review	annual Fee (Continuing Review)	Amendments requiring review at a convened meeting	Expedited Review	Determination of Exempt Status	For cause audits (regardless of funding source)
Industry-sponsored protocols	$2500	$500 * (for projects initially reviewed at a convened meeting)	$500	$1000 for initial review	$300	$1,000 **
Protocols funded by federal grants, no indirect costs—charge IRB fee as direct cost	$750	$0	$0	$500 for initial review	$0	$1,000 **

1. Fees will be assessed on all studies supported by for-profit sponsors and/or agencies/foundations that do not otherwise cover IRB fee through indirect costs to the institution or other mechanisms and contractually allow for processing of IRB fees.

2. No fees are assessed for modifications that do not require review at a convened meeting, supplemental documents, and unanticipated problems associated with these protocols.

3. The IRB will not charge for Single Patient Treatments, Emergencies, or if a study is in long term Follow-up, Data Analysis, Non-Human Research and Compassionate Use Protocol.

*Annual fees will be assessed yearly from the date of approval if the project remains open (this is regardless of risk or renewal process)

**The $1000 Charge will be assessed for the following for-cause audits regardless of funding status; this fee will be submitted to the investigator/department for payment. For cause audits include the following:

1. Studies which expire in approval without receipt of a continuing or final report will generate a for-cause audit and the department will be assessed the audit fee. (exception-studies which were determined to be exempt)
2. The IRB determines an investigator may have serious and continuing non-compliance with their research and request a for cause audit.
3. Projects that require audit because of suspected scientific misconduct.

If a project approval has expired and the investigators wishes to continue, the project will require additional review and will be charged as an initial review.